v3.26.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
ASSETS    
Cash and cash equivalents $ 18,738 $ 2,998
Zydus agreements escrow receivable (Note R) 7,616 0
Zydus agreements contract assets (Note R) 32,860 0
Accounts receivable 14,725 1,831
Prepaid expenses 2,853 785
Assets held for sale 0 121,554
Other current assets 2,018 1,089
Total current assets 78,810 133,436
Property, plant and equipment, net of accumulated amortization and depreciation of $47,977 and $47,468 at June 30, 2026 and December 31, 2025, respectively 14,322 15,470
Operating lease right-of-use assets 7,205 7,744
Goodwill 24,092 24,092
Acquired intangible assets, net of accumulated amortization of $17,482 and $17,325 at June 30, 2026 and December 31, 2025, respectively 2,880 3,037
Equity method investment in MiNK Therapeutics, Inc. 25,452 24,277
Other long-term assets 3,856 3,307
Total assets 172,692 226,798
LIABILITIES AND STOCKHOLDERS' DEFICIT    
Short-term debt 30,068 44,655
Current portion, liability related to sale of future royalties and milestones (Note H) 113,671 109,323
Current portion, operating lease liabilities 1,102 1,034
Accounts payable 58,984 82,987
Accrued liabilities 27,515 34,223
Liabilities held for sale 0 50,738
Other current liabilities 480 529
Total current liabilities 231,820 323,489
Liability related to sale of future royalties and milestones, net of current portion (Note H) 135,794 169,660
Deferred revenue 1,143 1,143
Operating lease liabilities, net of current portion 9,538 10,108
Other long-term liabilities 247 259
Commitments and contingencies
STOCKHOLDERS" DEFICIT    
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 42,615,618 and 35,320,397 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively 427 353
Additional paid-in capital 1,945,037 1,911,740
Accumulated other comprehensive loss (450) (439)
Accumulated deficit (2,144,089) (2,182,765)
Total stockholders' deficit attributable to Agenus Inc. (199,075) (271,111)
Non-controlling interest (6,775) (6,750)
Total stockholders' deficit (205,850) (277,861)
Total liabilities and stockholders' deficit 172,692 226,798
Related Parties [Member]    
ASSETS    
Related party note receivable from MiNK Therapeutics, Inc. 0 5,179
Due from related parties (MiNK Therapeutics, Inc.) 16,075 15,435
Series A-1 convertible preferred stock [Member]    
STOCKHOLDERS" DEFICIT    
Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at June 30, 2026 and December 31, 2025; liquidation value of $34,371 at June 30, 2026 $ 0 $ 0